Adenosine A(2A) Receptors Are Upregulated in Peripheral Blood Mononuclear Cells from Atrial Fibrillation Patients
Por:
Godoy-Marin, H, Duroux, R, Jacobson, KA, Soler, C, Colino-Lage, H, Jimenez-Sabado, V, Montiel, J, Hove-Madsen, L, Ciruela, F
Publicada:
1 abr 2021
Resumen:
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia seen in clinical practice. While some clinical parameters may predict the transition from paroxysmal to persistent AF, the molecular mechanisms behind the AF perpetuation are poorly understood. Thus, oxidative stress, calcium overload and inflammation, among others, are believed to be involved in AF-induced atrial remodelling. Interestingly, adenosine and its receptors have also been related to AF development and perpetuation. Here, we investigated the expression of adenosine A2A receptor (A2AR) both in right atrium biopsies and peripheral blood mononuclear cells (PBMCs) from non-dilated sinus rhythm (ndSR), dilated sinus rhythm (dSR) and AF patients. In addition, plasma adenosine content and adenosine deaminase (ADA) activity in these subjects were also determined. Our results revealed increased A2AR expression in the right atrium from AF patients, as previously described. Interestingly, increased levels of adenosine content and reduced ADA activity in plasma from AF patients were detected. An increase was observed when A2AR expression was assessed in PBMCs from AF subjects. Importantly, a positive correlation (p = 0.001) between A2AR expression in the right atrium and PBMCs was observed. Overall, these results highlight the importance of the A2AR in AF and suggest that the evaluation of this receptor in PBMCs may be potentially be useful in monitoring disease severity and the efficacy of pharmacological treatments in AF patients.
Filiaciones:
Godoy-Marin, H:
Univ Barcelona, Inst Neurosci, Fac Med & Hlth Sci, Dept Pathol & Expt Therapeut,Pharmacol Unit, Lhospitalet De Llobregat 08907, Spain
Inst Invest Biomed Bellvitge, Neuropharmacol & Pain Grp, Neurosci Program, IDIBELL, Lhospitalet De Llobregat 08907, Spain
Duroux, R:
NIDDK, Mol Recognit Sect, Lab Bioorgan Chem, NIH, Bethesda, MD 20892 USA
Jacobson, KA:
NIDDK, Mol Recognit Sect, Lab Bioorgan Chem, NIH, Bethesda, MD 20892 USA
Soler, C:
Inst Invest Biomed Bellvitge, Neuropharmacol & Pain Grp, Neurosci Program, IDIBELL, Lhospitalet De Llobregat 08907, Spain
Univ Barcelona, Immunol Unit, Dept Pathol & Expt Therapeut, Fac Med & Hlth Sci,Inst Neurosci, Lhospitalet De Llobregat 08907, Spain
Colino-Lage, H:
Barcelona Biomed Res Inst, IIBB CSIC, Barcelona 08036, Spain
Biomed Res Inst St Pau, IIB St Pau, Barcelona 08025, Spain
Jimenez-Sabado, V:
Biomed Res Inst St Pau, IIB St Pau, Barcelona 08025, Spain
CIBERCV, Madrid 28029, Spain
Montiel, J:
Hosp Santa Creu & Sant Pau, Dept Cardiac Surg, Barcelona 08036, Spain
Hove-Madsen, L:
Barcelona Biomed Res Inst, IIBB CSIC, Barcelona 08036, Spain
Biomed Res Inst St Pau, IIB St Pau, Barcelona 08025, Spain
CIBERCV, Madrid 28029, Spain
Ciruela, F:
Univ Barcelona, Inst Neurosci, Fac Med & Hlth Sci, Dept Pathol & Expt Therapeut,Pharmacol Unit, Lhospitalet De Llobregat 08907, Spain
Inst Invest Biomed Bellvitge, Neuropharmacol & Pain Grp, Neurosci Program, IDIBELL, Lhospitalet De Llobregat 08907, Spain
Green Published, gold
|